Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Teva Pharma Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (156)
ARTG (126)
Prescription medicine registration (23)
Australian Public Assessment Report (AusPAR) (7)
Prescription medicine decision summary (3)
Section 14, TGO91 consent (2)
Designation or determination (1)

Date

2024 (120)
2023 (16)
2022 (13)
2021 (68)
2020 (23)
2019 (11)
2018 (6)
2017 (8)
2016 (25)
2015 (9)
2012 (2)
2011 (4)
2010 (1)
2006 (3)
2002 (7)
1995 (2)

Results for "[search-keyword]"

Search

Sponsor content

318 result(s) found, displaying 101 to 110

TE-LENALIDOMIDE lenalidomide (as hydrochloride monohydrate) 5 mg capsule blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-LENALIDOMIDE lenalidomide (as hydrochloride monohydrate) 25 mg capsule blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-METHYLPHENIDATE XR methylphenidate hydrochloride 36 mg modified release tablet bottle Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-METHYLPHENIDATE XR methylphenidate hydrochloride 27 mg modified release tablet bottle Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-METHYLPHENIDATE XR methylphenidate hydrochloride 54 mg modified release tablet bottle Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-DASATINIB dasatinib 50 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-DASATINIB dasatinib 70 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
DASATINIB-TEVA dasatinib 70 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
DASATINIB-TEVA dasatinib 20 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
DASATINIB-TEVA dasatinib 50 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd

Pages

First page
Previous page
…
Page 7
Page 8
Page 9
Page 10
Current page 11
Page 12
Page 13
Page 14
Page 15
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.